



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/63, 15/67, 15/85, 15/12, 5/10, 7/00, C12P 21/02, A61K 48/00		A1	(11) International Publication Number: WO 99/57290
		(43) International Publication Date: 11 November 1999 (11.11.99)	
(21) International Application Number: PCT/US99/09748 (22) International Filing Date: 4 May 1999 (04.05.99) (30) Priority Data: 60/084,236 5 May 1998 (05.05.98) US (71)(72) Applicant and Inventor: VOELLMY, Richard [US/US]; Apartment 2612, 650 West Avenue, Miami, FL 33139 (US). (74) Agents: SHARKEY, Richard, G. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: MOLECULAR REGULATORY CIRCUITS TO ACHIEVE SUSTAINED ACTIVATION OF GENES OF INTEREST BY A SINGLE STRESS			
(57) Abstract The exposure of cells, tissues and organs to "stress", such as elevated temperature, stimulates production of active heat stress transcription factors (HSF), which in turn, induce expression of genes regulated by stress promoters. Normally, the activity of stress promoters declines after cells, tissues and organs are returned to a normal condition. Mutant forms of HSF, however, can constitutively transactivate stress genes, in the absence of stress. By taking advantage of such mutant HSF, molecular circuits can be devised to provide a sustained expression of a gene of interest using a single application of stress. One form of molecular circuit comprises (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a promoter activatable by stress and by the transcription factor, wherein the stress-activatable promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the second promoter and the gene of interest are operably linked.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MOLECULAR REGULATORY CIRCUITS TO ACHIEVE SUSTAINED ACTIVATION OF GENES OF INTEREST BY A SINGLE STRESS

TECHNICAL FIELD

5 The present invention relates generally to methods for controlling expression of a foreign gene. In particular, the present invention relates to methods for inducing sustained gene expression by a single application of stress.

BACKGROUND OF THE INVENTION

10 Exposure of cells, tissues and organs to "stress," such as elevated temperature, heavy metals, oxidants, chemicals interfering with mitochondrial function, alcohols, hypoxia, hyperosmotic and hypoosmotic environments, amino acid analogues, and benzoquinone ansamycins results in the activation or enhanced activity of a group of genes known as heat shock or stress (*hsp*) genes. See, for example, Scharf *et al.*,
15 "Heat Stress Promoters and Transcription Factors," in *Results and Problems in Cell Differentiation* 20, Nover (Ed.), pages 125-162 (Springer-Verlag 1994). When cells, tissues and organs are returned to a normal condition, stress gene activity declines, until it reaches the low pre-stress level.

 Stress genes encode a small number of heat shock or stress protein (Hsp)
20 families. Major families of stress proteins are distinguished on the basis of molecular weight and amino acid sequence. See, for example, Nover and Scharf, *Cell. Mol. Life Sci.* 53:80 (1997). They include Hsp110 (Hsp's with a subunit molecular weight of about 110 kDa), Hsp104, Hsp90, Hsp70, Hsp60, Hsp27, Hsp10 and ubiquitin. Many of these Hsp's are molecular chaperones that participate in such basic cellular processes as
25 protein folding, protein degradation and protein trafficking.

 Promoter regions of stress genes typically include so-called heat shock element (HSE) sequences. These sequences are essential to render the genes activatable by stress. HSE provide binding sites of proteins named heat shock transcription factors

(HSF). See, for example, Wu, "Heat Shock Transcription Factors: Structure and Regulation," in *Annu. Rev. Cell Dev. Biol.* 11:441 (1995); Nover and Scharf, *Cell. Mol. Life Sci.* 53:80 (1997). Mammalian cells can express at least three different HSF. It is thought that the factor termed HSF1 is responsible for the regulation of *hsp* genes by stress. HSF1 is continuously and ubiquitously expressed in mammalian cells. In the absence of stress, the factor is present in an inactive form, unable to bind HSE sequences of stress gene promoters and to enhance their transcription. During stress, HSF1 is activated, and in the activated form, it binds HSE DNA and stimulates transcription of stress genes. Subsequent to a stressful event, the factor relatively rapidly returns to its inactive form. Consequently, transcription of stress genes ceases. Mutant forms of HSF1 have been constructed that are capable of constitutively transactivating stress genes, in the absence of stress.

Promoters of stress genes have been linked to genes of interest to render the genes activatable by stress. Constructs of this kind were used to prepare cell lines, in which the gene of interest could be activated by heat or some other form of stress. For example, cell lines have been prepared that contain a stress gene promoter-controlled growth hormone gene. Dreano *et al.*, *Gene* 49:1 (1986). Moreover, transgenic flies and transgenic nematodes have been produced that express a β -galactosidase gene under stress control. See, for example, Voellmy and Ananthan, U.S. Patent No. 5,346,812, and Candido and Jones, *Trends Biotechnol.* 14:125 (1996), and Jones *et al.*, *Toxicology* 109:119 (1996).

A major drawback of the use of stress promoters to control regulation of a gene of interest is that gene expression induced by a stress promoter can be maintained beyond the duration of the stress treatment only under conditions of extreme stress. Yet such extreme conditions are incompatible with cell survival.

Therefore, a need exists for a means to take advantage of stress-induced gene regulation under conditions that do not endanger cell viability.

SUMMARY OF THE INVENTION

The present invention provides molecular circuits that can be activated by stress, and that regulate expression of a gene of interest.

In particular, the present invention provides molecular circuits comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress and by the transcription factor, wherein the first promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the second promoter and the gene of interest are operably linked. In a variation of this type of molecular circuit, the molecular circuit comprises a gene of interest that encodes a transactivator, and the molecular circuit further comprises a nucleic acid molecule comprising a second gene of interest and a promoter activatable by the transactivator, wherein the second gene of interest and the transactivator-activatable promoter are operably linked. The molecular circuits may comprise two separate nucleic molecules, or the molecular circuits may comprise a single nucleic acid molecule that contains the first and second nucleic acid molecules.

The present invention also includes molecular circuits comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress, wherein the first promoter and the transcription factor gene are operably linked, (b) a second nucleic acid comprising a gene encoding the transcription factor and a second promoter activatable by the transcription factor, wherein the second promoter and the transcription factor gene are operably linked, and (c) a third nucleic acid molecule that comprises a gene of interest and a third promoter activatable by the transcription factor, wherein the third promoter and the gene of interest are operably linked. These molecular circuits may comprise (a) three separate nucleic acid molecules, (b) the third nucleic acid molecule and a single nucleic acid molecule that comprises the first nucleic acid molecule and the second nucleic acid molecule, or (c) a single nucleic acid molecule comprises the first nucleic acid molecule, the second nucleic acid molecule, and the third nucleic acid molecule.

The present invention further contemplates molecular circuits comprising (a) a first nucleic acid molecule that comprises a gene encoding a first transcription factor and a first promoter activatable by stress, wherein the first promoter and the first transcription factor gene are operably linked, (b) a second nucleic acid
5 comprising a gene encoding a second transcription factor and a second promoter activatable by the first transcription factor and the second transcription factor, wherein the second promoter and the second transcription factor gene are operably linked, and (c) a third nucleic acid molecule that comprises a gene of interest and a third promoter activatable by the second transcription factor, wherein the third promoter and the gene
10 of interest are operably linked. These molecular circuits may comprise (a) three separate nucleic acid molecules, (b) the third nucleic acid molecule and a single nucleic acid molecule that comprises the first nucleic acid molecule and the second nucleic acid molecule, or (c) a single nucleic acid molecule comprises the first nucleic acid molecule, the second nucleic acid molecule, and the third nucleic acid molecule.

15 The present invention also contemplates molecular circuits comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress, wherein the first promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest, the transcription factor gene, and a second promoter
20 activatable by the transcription factor, wherein the second promoter is operably linked with the gene of interest and the transcription factor gene. These molecular circuits may comprise two nucleic molecules, or the molecular circuits may be contained within a single nucleic acid molecule that contains the first and second nucleic acid molecules.

In molecular circuits of the present invention, the transcription factor can
25 be, for example, a mutated heat shock transcription factor (HSF) or a chimeric transcription factor. A suitable mutated HSF can be derived from a vertebrate HSF or from an insect HSF. For example, a suitable vertebrate HSF can be a mammalian HSF or an avian HSF.

The molecular circuits described herein can be contained within a single
30 expression vector. Alternatively, molecular circuit nucleic acid molecules can be

contained within a set of expression vectors, wherein each expression vector contains one or two molecular circuit nucleic acid molecules.

The present invention also contemplates recombinant host cells that comprise a molecular circuit. The molecular circuit may have the form of a single
5 expression vector or an expression vector set, as described above. Suitable eukaryotic host cells include insect cells, avian cells, yeast cells, and mammalian cells.

The present invention further contemplates methods of producing a protein of interest, comprising the steps of: (a) culturing such recombinant host cells, (b) stimulating the first promoter by exposing the cultured recombinant cells to stress,
10 and (c) isolating the protein of interest from the cultured recombinant host cells, wherein the protein of interest is expressed by the gene of interest. Step (b) can be achieved, for example, by heating the recombinant host cells.

The present invention also contemplates viruses that comprise an expression vector described above. Suitable viruses include adeno-associated viruses,
15 adenoviruses, *Herpes simplex* viruses, alphaviruses, and pox viruses.

The present invention also includes pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and either an expression vector or an expression vector set, as described above. Alternatively, a pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier and a virus,
20 as described above.

The present invention further contemplates methods of treating a subject with a protein of interest, comprising the steps of: (a) administering to a subject a pharmaceutical composition described above, and (b) applying heat to the area of the subject in need of the protein of interest, wherein the heat treatment results in the
25 stimulation of the expression of the gene of interest.

The present invention also includes methods of stimulating the expression of a gene of interest in a recombinant cell, comprising the steps of: (a) producing a recombinant host cell by introducing into a host cell either the expression vector, or an expression vector set, as described above, and (b) exposing the recombinant
30 host cell to a condition of stress, wherein the stress exposure stimulates the first promoter

to increase expression of the gene operably linked to the first promoter, which in turn, results in the stimulation of expression of the gene of interest.

These and other aspects of the present invention will become evident
5 upon reference to the following detailed description and attached drawings. In addition, various references are identified below and are incorporated by reference in their entirety.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic of the elements of a type 1 switch and shows the interactions between the elements. "HSE" refers to heat shock element sequences that are binding sites of heat shock transcription factor (HSF) contained in typical *hsp* gene promoters. A "dHSF" is a constitutively active heat shock transcription factor that has
15 been mutated to remove an element that represses the transcriptional ability of the factor.

Figure 2 is a schematic of the elements of a type 2 switch and shows the interactions between the elements. "LexAdHSF" refers to a hybrid transcription factor gene encoding a constitutively active HSF1 with its heat shock element DNA-binding
20 domain replaced by the DNA-binding domain of bacterial repressor *LexA*.

Figure 3 is a schematic of the elements of one example of a type 3 switch. "LexA-Act. Domain" refers to a hybrid transcription factor gene encoding the DNA binding and dimerization domains of LexA fused to a transcriptional activation domain.

25 Figure 4 is a schematic of the elements of another form of type 3 switch. "EcR/RXR" refers to a heterodimeric ecdysone receptor composed of an ecdysone receptor (EcR) and a retinoid receptor (RXR) subunit.

Figure 5 shows the nucleotide and amino acid sequences of the human heat shock transcription factor HSF1 (SEQ ID NOs: 1 and 2, respectively).

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

5 In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the invention.

 As used herein, "nucleic acid" or "nucleic acid molecule" refers to any of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of
10 ligation, scission, endonuclease action, and exonuclease action. Nucleic acids can be composed of monomers that are naturally-occurring nucleotides (such as deoxyribonucleotides and ribonucleotides), or analogs of naturally-occurring nucleotides (*e.g.*, α -enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have modifications in sugar moieties
15 and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base
20 moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and
25 the like. The term "nucleic acid" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

As used herein, the term "immunomodulator" includes cytokines, stem cell growth factors, lymphotoxins, co-stimulatory molecules, hematopoietic factors, and synthetic analogs of these molecules.

5 An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes an immunomodulator that has been separated from the genomic DNA of a cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism.

10 An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. That a particular protein preparation contains an isolated polypeptide can be shown by the appearance of a single band following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the protein preparation and Coomassie Brilliant Blue staining of the gel.

15 A "promoter" is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.

20 A "regulatory element" is a nucleotide sequence that modulates the activity of a promoter. For example, a regulatory element may contain a nucleotide sequence that binds with cellular factors enabling transcription exclusively or preferentially in particular cells, tissues, or organelles. These types of regulatory elements are normally associated with genes that are expressed in a "cell-specific," "tissue-specific," or "organelle-specific" manner.

25 As used herein, a "transcription factor" is a protein that binds to a nucleic acid and thereby influences its transcription by altering rates of transcription initiation or elongation.

A "transactivator" is a transcription factor that enhances transcription initiation or elongation.

As used herein, a "chimeric transcription factor" is a protein comprising a DNA binding domain of one protein and a transcriptional activation domain of another protein. For example, a chimeric transcription factor may comprise a LexA DNA binding domain and a heat shock transcription factor activation domain.

In the case of a monomeric or homooligomeric transcription factor, the term "transcription factor gene" refers to the sequence coding for the factor polypeptide, supplemented with appropriate control elements that ensure proper termination of transcription, processing of RNA product, and translation. In the circuits described herein, the transcription factor gene is operably linked to a promoter activatable by stress and/or the transcription factor. In the case of heterooligomeric transcription factors, the term "transcription factor gene" refers to coding sequences required for the synthesis of all subunits, each supplemented with control elements, as described above.

To construct the circuits of the kind described herein, at least one of the sequences encoding a subunit of a heterooligomeric transcription factor needs to be linked to an appropriately regulatable promoter (e.g., activatable by stress and/or the transcription factor). The promoter-linked sequences may be present in a single nucleic acid or may be in separate nucleic acids. Alternatively, the sequences may be arranged in tandem, separated by internal ribosome binding sites, and the entire arrangement of sequences may be linked to a single promoter.

A "heterodimeric transcription factor" is a transcription factor consisting of two different subunit polypeptides. An example of a heterodimeric transcription factor is the ecdysone receptor-retinoic acid receptor molecule described herein.

A "heat shock element (HSE)" is a nucleic acid molecule that binds with a heat shock transcription factor (HSF) to stimulate gene expression. HSE sequences usually contain multiple repeats of the sequence module "NGAAN" that are arranged in alternating orientation. See, for example, Scharf *et al.*, "Heat Stress Promoters and Transcription Factors," in *Results and Problems in Cell Differentiation* 20, Nover (Ed.),

pages 125-162 (Springer-Verlag 1994). Typically, at least three modules of the sequence need to be present to constitute a functional HSE sequence.

"Complementary DNA (cDNA)" is a single-stranded DNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a
5 primer complementary to portions of mRNA is employed for the initiation of reverse transcription. Those skilled in the art also use the term "cDNA" to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand.

The term "expression" refers to the biosynthesis of a gene product. For
10 example, in the case of a structural gene, expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides. The regulatory circuits described herein can be used to stimulate expression of a gene of interest to produce a protein of interest. Regulatory circuits can also be used to control the expression of an anti-sense gene, a ribozyme gene or an external guide sequence gene in
15 which a nucleic acid, rather than a protein, is the relevant end product.

A "cloning vector" is a nucleic acid molecule, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign nucleotide sequences can be inserted in a determinable
20 fashion without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.

An "expression vector" is a nucleic acid molecule encoding a gene that is
25 expressed in a host cell. Typically, gene expression is placed under the control of a promoter. Such a gene is said to be "operably linked to" the promoter.

A "recombinant host" may be any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector. This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned
30 gene(s) in the chromosome or genome of the host cell.

In recombinant constructs described below, a regulatory element or a promoter controls the expression of a gene which is not associated with the regulatory element or promoter in nature. Such a construct is said to comprise a regulatory element or promoter and a "foreign gene." For example, a nucleic acid molecule comprising a promoter activatable by a heat shock transcription factor operably linked to a cytokine gene contains a cytokine gene as the foreign gene. The foreign gene is a type of "gene of interest," and the product of a foreign gene is a "foreign protein," which is a type of "protein of interest."

In eukaryotes, RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA. A nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA. The RNA transcript is termed an "anti-sense RNA" and a nucleic acid molecule that encodes the anti-sense RNA is termed an "anti-sense gene." Anti-sense RNA molecules are capable of binding to mRNA molecules, resulting in an inhibition of mRNA translation.

A "ribozyme" is a nucleic acid molecule that contains a catalytic center. The term includes RNA enzymes, self-splicing RNAs, self-cleaving RNAs, and nucleic acid molecules that perform these catalytic functions. A nucleic acid molecule that encodes a ribozyme is termed a "ribozyme gene."

An "external guide sequence" is a nucleic acid molecule that directs the endogenous ribozyme, RNase P, to a particular species of intracellular mRNA, resulting in the cleavage of the mRNA by RNase P. A nucleic acid molecule that encodes an external guide sequence is termed an "external guide sequence gene."

As used herein, a "gene of interest" is an RNA polymerase II gene encoding an RNA product or a polypeptide product.

2. Construction of a Type 1 Circuit

Several regulatory circuits are described herein that have the general feature that their use permits sustained activation of expression of a gene of interest by a single application of stress. Gene activity regulated by these circuits does not subside subsequent to the activating stress.

The most simple circuit consists of two elements: (1) a gene of interest functionally linked to a stress gene promoter, and (2) a gene encoding a constitutively activated mutated heat shock transcription factor (HSF), which is also functionally linked to a stress gene promoter. An example of a type 1 circuit is illustrated in Figure 1. The two elements may be delivered into cells as a single nucleic acid or as separate nucleic acids. In the cells, both genes are either silent or expressed at appropriately low levels in the absence of stress. When the cells are stressed, promoters in both elements are activated by endogenous HSF, which results in the expression and accumulation of the gene product of interest and of mutated HSF. Mutated HSF continues to activate transcription of both the gene of interest and its own gene, resulting in the synthesis of more product of interest and mutated HSF. This cycle continues even if the cells are no longer under stress. Consequently, the gene of interest will remain active until such time that the cell has exhausted its capacity to transcribe and translate nucleic acids. Thus, this two-element system has the desired feature of permitting the sustained activation by stress of a gene of interest by a single stress.

When preparing the elements of the circuit, a number of factors need to be considered. First, the stress promoter controlling the expression of mutated HSF preferably should be tightly stress-regulated. Leaky expression from the promoter may result in accumulation of an amount of mutated HSF that is sufficient to stimulate expression from the promoter, resulting in gradually increased levels of HSF and ultimately in the full activation of the gene of interest. An example of a tightly regulated stress promoter is the promoter regulating the expression of the human *hsp70B* gene. Voellmy *et al.*, *Proc. Natl. Acad. Sci. USA* 82:4949 (1985).

In addition to the choice of promoter, the level of basal expression of mutated HSF can be reduced by other manipulations well known in the art. For

example, the half-life of the mRNA encoding mutated HSF can be reduced by including elements enhancing mRNA degradation in the 3' nontranslated sequence. Chen and Shyu, *Trends Biochem. Sci.* 20:465 (1995). It is also possible to reduce the rate of translation by introducing palindromic sequences of suitable length in the 5' nontranslated sequence of the mutated *HSF1* gene (see Muhlrads *et al.*, *Mol. Cell. Biol.* 15:2145 (1995), and references cited therein). The stability of mutated HSF1 can also be reduced by insertion of residues, deletion of sequence elements that confer structural stability, or introduction of protease cleavage sites. The operation of the circuit and effects of manipulations of the type described above can be assessed by construction of a test circuit and analysis of its performance, as described below.

A stress-regulated test circuit is described in Example 1. Briefly, a first construct can be prepared by inserting into a suitable plasmid vector a fragment containing the human *hsp70B* promoter and a fragment containing the entire coding sequence of firefly luciferase such that the stress promoter controls expression of the luciferase sequence. A second plasmid vector can be constructed that contains a stress promoter linked to a gene encoding a mutated HSF, for example HSF1d202-316, or a derivative containing one or more of the modifications discussed before to reduce level of accumulation. These constructs are prepared using routine subcloning procedures well known in the art. The constructs are then co-transfected into a suitable cell such as, for example, human HeLa cells, using a standard technique, such as calcium phosphate transfection, liposome-mediated transfection, electroporation, using viral vectors, and the like. Techniques for introducing vectors into eukaryotic cells are described, for example, by Ausubel *et al.* (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, (John Wiley & Sons, Inc. 1995), and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991).

Control cells are singly transfected with the stress promoter-luciferase construct. Transfection efficiency may be estimated by co-transfection of a suitable reporter gene such as, for example, a gene expressing constitutively a green fluorescent protein, that can be readily monitored by cytometry. One day after transfection, one of every two parallel cultures is briefly heat-treated (one hour at 42-44°C in the case of

HeLa cells) and then incubated at normal temperature (37°C in the case of HeLa cells) for another two days. Cells are then harvested, and luciferase activity assays are carried out.

No luciferase activity will be measured in cells singly transfected with the stress promoter-luciferase construct that had not been heat-treated, and only low levels of activity will be detected in heat-treated cells. Luciferase and its mRNA are relatively unstable in mammalian cells. Although expressed at a high level during and immediately following heat treatment, synthesis declines after heat treatment, and after two days only little of the enzyme initially synthesized is still present. If the circuit is functional, cells that have not been heat-treated but have been co-transfected with both constructs will have low to undetectable luciferase activity, whereas heat-treated, co-transfected cells will have levels of luciferase that are many times higher than those measured in singly transfected cells. High levels of luciferase are present in the heat-treated, co-transfected cells because mutated HSF1 is expressed and maintained, and the factor continuously stimulates expression from the luciferase gene. If levels of luciferase are unacceptably elevated in not-heat-treated, co-transfected cells, some of the manipulations described before to reduce levels of mutated HSF1 can be carried out, and their effects assessed in the test system.

Any stress promoter may be used in the circuit. A stress promoter as used herein is defined as a promoter of a known stress-regulated gene. Typically such stress promoters contain one or several HSE sequences which are characterized as elements containing multiple modules of the sequence NGAAN that are arranged in alternating orientation. Typically, at least three modules need to be present to constitute a functional HSE sequence. Three or more modules do not necessarily have to be arranged as an uninterrupted array. Sequences such as NGAANNNTTCNNNNNNNTTCNNGAAN can be functional HSEs. Amin *et al.*, *Mol. Cell. Biol.* 8:3761 (1988). The functionality of a putative HSE can be tested by introducing it as one or several copies upstream from a basal promoter that is functionally linked to a convenient reporter gene. Amin *et al.*, *Mol. Cell. Biol.* 7:1055

(1987). The resulting constructs are tested by introduction into a cell of choice and analysis of their activity in the stressed (e.g., heat-treated) and not-stressed cells.

Examples of suitable stress-inducible promoters include vertebrate and insect *hsp* promoters. Preferred vertebrate *hsp* promoters include *hsp90 α* , *hsp70*, and
5 *hsp25-27* promoters. An example of a preferred human promoter is the human *hsp70B* promoter. Additional suitable promoters are known to those of skill in the art. See, for example, Nover, *Enzyme Microb. Technol.* 9:130 (1987), Nover, *Heat Shock Response* (CRC Press, Inc. 1991), Günther and Walter, *Experientia* 50:987 (1994), Craig *et al.*, *Cold Spring Harbor Symposia on Quantitative Biology* 60:441 (1995), Scharf *et al.*,
10 "Heat Stress Promoters and Transcription Factors," in *Results and Problems in Cell Differentiation* 20, Nover (Ed.), pages 125-162 (Springer-Verlag 1994), Voellmy, *Crit. Rev. Eukaryotic Gene Expr.* 4:357 (1994), and Nover and Scharf, *Cell. Mol. Life Sci.* 53:80 (1997).

A suitable stress promoter can also be a synthetic promoter, constructed
15 by introduction of one or several HSE sequences, either isolated or amplified from natural stress genes, or synthesized chemically, into a non-stress-regulated promoter by recombinant techniques. A suitable stress promoter also includes a promoter containing variant HSE sequences. Single substitutions in the modules constituting an HSE are frequently tolerated. HSE are well conserved throughout the animal and plant
20 kingdoms. A stress promoter therefore does not need to originate from a gene of the organism, in which or in cells of which a circuit will be established. For example, a fly stress promoter may be used in a functional circuit introduced in a mammalian cell. Amin *et al.*, *Mol. Cell. Biol.* 5:197 (1985).

A gene of interest may be any gene encoding a useful protein. The
25 protein may be a secreted protein or a protein that is not secreted. The gene may originate from the cell type in which a circuit is established or from any other cell type. The gene may be a prokaryotic or eukaryotic gene.

Examples of suitable genes for expression include immunomodulators, such as cytokines, co-stimulatory molecules, stem cell growth factors, lymphotoxins,
30 such as tumor necrosis factor, and hematopoietic factors, such as interleukins (e.g.,

interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-6, IL-10 and IL-12), colony stimulating factors (e.g., granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor), interferons (e.g., interferons- α , - β and - γ), the stem cell growth factor designated "S1 factor," erythropoietin and thrombopoietin. Other suitable genes
5 for expression include genes encoding toxins or protoxins, stress proteins, foreign antigens, blood factors, polypeptide hormones, and other therapeutic proteins. More generally, the regulatory circuits described herein can be used to express any protein, in particular any protein in need of posttranslational modification, such as phosphorylation, glycosylation, methylation, acetylation, ubiquitination, and the like.

10 Vertebrate heat shock transcription factors (HSF) comprise several conserved sequence elements as well as a conserved functional element that provide guidance for the design of mutated HSF. Conserved sequence elements include an amino-terminally located HSE DNA-binding domain having a helix-turn-helix binding motif defined by mutational and structural (X-ray crystallography and NMR) analyses
15 that is related to a motif in a bacterial sigma factor. Farther inside are two hydrophobic repeat regions of the 3,4-type, named HR1 and HR2. At least HR1 is essential for formation of the homotrimeric form of the factor, which is the form present in stressed cells and capable to binding HSE sequences. Farther inside, and separated from HR2 by more than 50 residues, is a third hydrophobic repeat, named HR3. HR2, HR3 and at
20 least one portion of HR1 are important in the normal regulation of the oligomeric status of HSF. However, as is described below, this aspect of HSF regulation is of no consequence in the context of the invention. Sequences close to the carboxy terminus of the factor, beginning just amino-terminally from HR3, and possibly including HR3, contain transcriptional activation domains.

25 As was shown for both mammalian HSF1 and *Drosophila* HSF, over-expression of the factor from an exogenous gene results in accumulation of predominantly homotrimeric factor. Thus, over-expression overrides a first level of regulation of the factor, which is the conversion of monomer to homotrimer. Still, the over-expressed factor is transcriptionally inert. Hence, a second level of regulation that
30 involves the conversion of inactive to active trimeric factor, is still intact. Inactive,

trimeric factor can be activated by stress or by manipulations that result in increased phosphorylation of the factor. It appears therefore that the second regulatory step is controlled by the level of phosphorylation of HSF.

Over-expressed HSF can also be activated by mutation. Deletion or
5 substitution in the region between about residues 185 and 315 in human HSF1 activates the factor as shown by its ability to transactivate a stress promoter-driven reporter gene in the absence of stress. This region includes HR2 and a stretch of about 115 residues immediately following the HR2 sequence. Specific example deletions are between residues 186 and 201, between 203 and 277, between 203 and 315 as well as various
10 small deletions between residues 186 and 201. Activating substitutions can be made, for example, at residues 189, 191, 279, 298, 290-292 and 307. See, for example, Zuo *et al.*, *Mol. Cell. Biol.* 14:7557 (1994), Zuo *et al.*, *Mol. Cell. Biol.* 15:4319 (1995), Newton, *et al.*, *Mol. Cell. Biol.* 16:839 (1996), and Xia *et al.*, *J. Biol. Chem.* 273:8749 (1998). Based on sequence conservation, corresponding regions in other HSF can be
15 readily identified.

DNA-binding domain sequences as well as HR sequences can be readily recognized in the sequence of an HSF. Mutations can be introduced into the HR2 region or in the region immediately following HR2. Many point mutations and virtually all sizable deletions in these regions will activate the factor. Activating
20 mutations can be identified, for example, by inserting a mutated HSF gene to be tested in an appropriate mammalian expression vector such as pCDNA3 (Invitrogen) containing a strong promoter such as a CMV promoter. The resulting construct can be introduced in a reporter cell line such as HeLa-CAT (Baler *et al.*, *J. Cell Biol.* 117:1151 (1992)) which contains a readily assayable reporter gene controlled by a stress
25 promoter. In HeLa-CAT cells, the reporter gene is a chloramphenicol acetyltransferase gene and the stress promoter is that of the human *hsp70B* gene. The mutated HSP will be expressed in the transfected reporter cell, and, if the mutation is activating, will transactivate the reporter gene. Alternatively, any suitable cell line may be used, and the transactivation ability of the mutated HSF can be detected as an increase in the level
30 of a stress proteins, such as an Hsp70 or a small HSP.

Studies of mammalian HSF have also shown that the HSE DNA-binding domain can be replaced by another DNA-binding domain with the result that the substituted HSF can activate a gene controlled by a promoter containing recognition sites for the substituted DNA-binding domain but no longer interacts with stress genes.

- 5 See, for example, Zuo *et al.*, *Mol. Cell. Biol.* 14:7557 (1994), and Newton, *et al.*, *Mol. Cell. Biol.* 16:839 (1996). The transcriptional activation domains of HSF can also be functionally substituted with other activation domains such as those active in other transcription factors. See, for example, Newton, *et al.*, *Mol. Cell. Biol.* 16:839 (1996). Finally, HR3 is dispensable. Zuo *et al.*, *Mol. Cell. Biol.* 15:4319 (1995); Newton, *et al.*,
10 *Mol. Cell. Biol.* 16:839 (1996).

Although human HSF, such as HSF1 and HSF2, and mutants thereof, are preferred heat shock transcription factors, other HSF (and their mutants) are suitable for use in a regulatory circuit described herein. In general, suitable HSF can be obtained from vertebrate sources, such as mammalian and avian sources, and from insect tissue.

- 15 Examples of particular additional HSF include *Drosophila melanogaster* Dm-HSF, murine Mm-HSF1 and MmHSF2, and *Gallus domesticus* Gd-HSF1, Gd-HSF2, and Gd-HSF3. See, for example, and Scharf *et al.*, "Heat Stress Promoters and Transcription Factors," in *Results and Problems in Cell Differentiation* 20, Nover (Ed.), pages 125-162 (Springer-Verlag 1994), and Nover and Scharf, *Cell. Mol. Life Sci.* 53:80 (1997).

- 20 Thus, a mutated HSF useful in the invention contains a DNA-binding domain, either from an HSF or, in circuits discussed below, from another DNA-binding protein, a trimerization domain (HR1 sequences), and a transcription activation domain, either from an HSF or from another source. Depending on the size of mutated HSF, a nuclear localization signal should also be included in its sequence.

- 25 Nucleic acid molecules for constructing the various elements of a regulatory circuit as described herein can be obtained from sources where they naturally occur, from cloned DNA regions, by reverse transcription of RNA from cells in which they are expressed, or by chemical synthesis. The molecules can be joined by standard molecular biology techniques, making use of restriction enzyme sites, adapters, linkers
30 or suitable PCR fragments.

3. Construction of a Type 2 Circuit

When the type 1 circuit is used, activation of the circuit not only results
5 in sustained expression of the gene of interest but also of endogenous stress genes. As a
consequence, cells containing the circuit will also accumulate stress proteins to higher
than normal levels, which may result in a tolerant state. In this state, a cell no longer
proliferates, and has a substantially enhanced resistance to proteotoxic insults.
Although this "resting" state can be maintained for a considerable period, it is suspected
10 that it cannot be sustained indefinitely. Thus, resting cells may eventually die. In some
applications, this may be a desired outcome. In other applications, however, one may
wish to use circuits that will not place cells in a resting state.

Figure 2 shows an example of another type of stress-inducible circuit
which will not stimulate continuous accumulation of stress proteins. The illustrative
15 type 2 circuit shown in Figure 2 differs from a type 1 circuit in three ways. First, the
type 2 circuit contains a mutated HSF in which the HSE DNA-binding domain has been
replaced by that of bacterial repressor *LexA*. This substituted factor no longer binds
stress promoters but promoters containing *LexA* recognition sites. The properties of
such a substituted factor have been documented in detail in the literature. See Zuo *et al.*
20 *Mol. Cell. Biol.* 14:7557 (1994), and Zuo *et al.*, *Mol. Cell. Biol.* 15:4319 (1995).
Second, the promoter controlling the expression of the gene of interest contains *LexA*
sites, so that it can be activated by a transcription factor recognizing these sites. See,
for example, Zuo *et al.* *Mol. Cell. Biol.* 15:4319 (1995), for a description of such a
promoter. Finally, the promoter controlling the expression of mutated HSF can be
25 activated either by endogenous HSF or by mutated HSF, because it contains both
functional HSE and *LexA* recognition sites. Such a promoter can be conveniently
constructed, for example, by inserting in a stress promoter one or more copies of the
known *LexA* motif. *LexA* motifs may be prepared chemically or may be retrieved from
an existing promoter containing such motifs. See, for example, U.S. Patent No.
30 4,833,080, and Garriga *et al.*, *Mol. Gen. Genet.* 236:125 (1992). DNA molecules

encoding the LexA repressor may be obtained from plasmid pRB500, American Type Culture Collection accession No. 67758.

A type 2 circuit operates as follows. After transient stress, endogenous HSF is activated, which results in expression and accumulation of mutated HSF. During and subsequent to stress, mutated HSF activates the promoter controlling the gene of interest as well as its own promoter, resulting in expression of the protein of interest as well as additional mutated HSF. The continued expression of mutated HSF stimulates synthesis of the protein of interest until the cell's capacity is exhausted.

Normally, stress genes are only expressed during the initial transient stress. Subsequent to this triggering stress, HSF is returned to its inactive form, stress gene expression ceases, and stress proteins are eliminated by the cell's proteolytic machinery. Expression of mutated HSF may further accelerate deactivation of HSF: as mutated HSF is expressed at levels greatly exceeding that of endogenous HSF, HSF may be forced into heterotrimers consisting of two molecules of mutated HSF and one molecule of HSF. Since a single HSE DNA-binding domain is incapable of specifically binding the HSE sequence, the heterotrimers will be incapable of binding to and activating stress genes. The operation of the circuit can be assessed by experiments analogous to those described before for the more simple circuit. Similar types of precautions and manipulations as described before for the simpler circuit will ensure that the circuit is tightly stress-regulated.

A *LexA* DNA-binding domain in a mutated HSF can be substituted by the DNA-binding domain of many other DNA-binding proteins as long as it is added to an HSF sequence at a point amino-terminal from the HR1. This follows from structural studies showing that the region between the HSE DNA-binding domain and the HR1 is unstructured and therefore can accommodate any DNA-binding domain. Further support comes from observations that the *LexA* DNA-binding domain can be added at various positions amino-terminally from HR1, and the resulting chimeras have similar DNA-binding properties. Thus, the positioning of a DNA-binding domain relative to HSF sequences is not constrained, and therefore, construction of functional chimeras can be accomplished without additional experimentation. For each modified type 2

circuit, the gene of interest needs to be controlled by a promoter containing binding sites for the particular DNA-binding domain present in mutated HSF.

The type 2 circuit contains a gene encoding a mutated HSF comprising a DNA-binding domain other than an HSE DNA-binding domain that is constitutively active when expressed. The transcription factor gene is controlled by a promoter that
5 can be activated by the mutated HSF and by endogenous HSF. This type of construct can be substituted by two constructs, the first comprising a transcription factor gene controlled by a stress promoter, and the second comprising a gene for the same transcription factor, or for a transcription factor binding the same nucleotide sequence
10 as the first transcription factor, controlled by a promoter activatable by the transcription factor. The type 2 circuit also contains a gene of interest controlled by a promoter that can be activated by the transcription factor of the first element.

15 4. Construction of a Type 3 Circuit

Other forms of circuits can be constructed in which the transcription factor is not mutated HSF. That is, any constitutively active transcription factor can be used in lieu of mutated HSF. A type 3 circuit is illustrated in Figure 3. Its elements are first a construct containing a gene for a constitutively active transcription factor, here
20 the synthetic factor LexA-activation domain, linked to a promoter activatable by both a stress and the transcription factor. Transcription factor LexA-activation domain contains the DNA-binding and dimerization domains of bacterial repressor *LexA* fused to a transcriptional activation domain. Alternatively, two constructs, contained in one or two nucleic acids, can be substituted. One of the constructions contains the
25 transcription factor gene linked to a stress promoter, and the other the transcription factor gene linked to a promoter responsive to the transcription factor. The second element is a construct containing a gene of interest controlled by a promoter responsive to the transcription factor.

Based on the same principles, more complex circuits can also be
30 constructed, in which sustained expression of a gene of interest is regulated by stress

and a second stimulus, which further decreases the likelihood of inadvertent activation. Such a system adds the new feature that expression of the gene of interest can be turned off at will.

An example of such a circuit that does not require mutated HSF and that, in addition, has the feature that a second stimulus is needed for activation of the gene of interest is illustrated in Figure 4. In the example, the transcription factor is an artificial factor composed of two subunits, *Drosophila* ecdysone receptor (EcR) and retinoid receptor (RXR). The transcription factor is only active in the presence of insect steroid hormone ecdysone or derivatives such as muristerone A. This factor has been developed to permit regulation of expression of genes of interest in mammalian cells by insect-specific steroid hormone. Ecdysone-Inducible Expression Kit (Invitrogen Corp.; San Diego, CA).

The illustrated type 3 circuit contains two elements. First, there are two sets of constructs expressing the two subunits of EcR/RXR. One set is regulated by stress promoters, and the other by an artificial promoter activatable by EcR/RXR. Second, a gene of interest, such as a cytokine gene, is controlled by a promoter activatable by EcR/RXR. This form of type 3 circuit operates as follows. In the absence of either one or both, stress and hormone, the gene of interest is silent. In the presence of hormone, a transient stress will activate one set of transcription factor genes, resulting in accumulation of EcR/RXR that is activated by hormone. Active factor will activate expression from the second set of transcription factor genes as well as the gene of interest. Because the transcription factor is continually produced, activation of the gene of interest is sustained. Upon withdrawal of the hormone, transcription factor is inactivated, and the autoactivating loop is interrupted. The gene of interest is no longer expressed, and the inactive transcription factor as well as protein of interest will eventually be degraded by intracellular proteolytic systems. This type of circuit may be particularly advantageous in the gene therapy setting, since it not only allows for local activation of a gene of interest by means of a local stress, but also for inactivation at the appropriate later time by means of withdrawal of systemically provided hormone.

The circuits provided herein may be amplified by the inclusion of additional elements. For example, the gene of interest may be substituted with the gene for a transactivator, such as the TAT protein of HIV. As an additional element, a construct encoding the gene of interest functionally linked to a promoter activated by the transactivator would be added. Once activated, this modified circuit may produce protein of interest at a higher rate than the original circuit.

5. Use of a Stress-Inducible Circuit to Prepare Recombinant Protein

The stress-inducible circuits described above can be applied to mass production of proteins of interest. For example, a first construct can contain a gene of interest linked to a stress promoter. A second construct can include a stress promoter-regulated mutated *HSF* gene. Alternatively, a gene of interest and a mutated *HSF* gene can be combined in a single vector. Suitable vectors include a plasmid, cosmid, or viral vector. The construct or constructs may contain additional genes, for example, a gene encoding a selectable marker to facilitate isolation of stable cell lines containing the construct(s). The construct(s) is introduced along with a selectable marker gene (such as *aminoglycoside 3'-phosphotransferase*, *dihydrofolate reductase*, *hygromycin- β -phosphotransferase*) into the host cell of choice by any method capable of delivering nucleic acids. Cell lines are selected, using a protocol adapted to the particular selectable marker employed.

Examples of suitable mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21; ATCC CRL 8544), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

In addition, suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL

1711), *Sf21AE*, and *Sf21* (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells. Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey *et al.*, "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel *et al.*, "The baculovirus expression system," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

Alternatively, the regulatory circuits described herein can be used to express a foreign protein in cultured yeast cells. Many yeast cloning vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEp vectors such as YEp13 and YCp vectors, such as YCp19. One skilled in the art will appreciate that there are a wide variety of suitable vectors for expression in yeast cells.

Cell lines are tested for low level of expression of the gene of interest in the absence of stress and sustained expression following brief exposure of the cells to a stress by a protocol analogous to that described for the test circuit. For mass production of protein of interest, cells are grown in large scale on solid support or in reactors depending on the cell type. When an appropriate cell number is reached, production of the protein of interest is initiated by brief stress treatment. The stress treatment may be a heat shock treatment as described for the test system, or it may be a transient exposure to any of the chemicals and conditions that are known to activate stress promoters. Alternatively, cells may be exposed to a mild stress, which may be maintained throughout the protein production period. Whereas cells normally down regulate expression from stress promoters after an initial burst of expression under such conditions, cells containing the regulatory circuit will not be able to do so, and expression will continue until the cells are exhausted.

Methods of inducing expression of genes controlled by a stress promoter are well-known to those of skill in the art. In addition to heat, stress promoters can be activated, for example, by heavy metals, alcohols, benzoquinone ansamycins, sulfhydryl-reactive reagents, and oxidants. See, for example, Hegde *et al.*, *J. Cell. Physiol.* 165:186 (1995), Wu, "Heat Shock Transcription Factors: Structure and Regulation," in *Annu. Rev. Cell Dev. Biol.* 11:441 (Annual Reviews, Inc. 1995), and Benndorf and Bielka, "Cellular Stress Response: Stress Proteins - Physiology and Implications for Cancer," in *Recent Results in Cancer Research* 143:130 (Springer-Verlag 1997).

At the appropriate time, cells are harvested and proteins of interest isolated or, if protein of interest is secreted, medium is collected and protein purified from medium using routine protocols. In the case of secreted proteins of interest, medium containing the proteins may be collected periodically or continuously. General methods for expressing and recovering foreign protein produced by a mammalian cell system is provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 163 (Wiley-Liss, Inc. 1996). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995).

6. Use of a Stress-Inducible Circuit for Gene Therapy

A regulatory circuit described herein can also be used to improve gene therapy methods. Gene therapy involves delivery of nucleic acids to cells of an individual, which may be expressed into therapeutic or prophylactically acting proteins in the target cells. In almost every conceivable situation, delivery cannot be targeted accurately to the area where therapy is necessary. Consequently, additional cells, tissues and organs that do not need the therapeutic nucleic acid are also provided with the nucleic acid. Oftentimes, such lack of proper targeting will have unwanted side effects. For example, if IL-2 needs to be expressed in a particular tissue to stimulate an

appropriate immune response, untargeted delivery of an IL-2 gene may result in systemic expression of the cytokine. It is well known that systemic introduction of IL-2 has severe toxic side effects. This problem can be avoided by delivery of the two-element regulatory circuit described before, which in this example case would
5 contain the IL-2 gene as the gene of interest. A standard delivery method can be used, resulting in delivery to the intended tissue as well as to certain other tissues. In the absence of a stress, the IL-2 gene of the circuit will be inactive. Activation and sustained expression of the gene in the proper location can then be achieved by transiently stressing the specific tissue, in which expression is desired.

10 Gene therapy can be targeted to monogenic diseases and to cancer. In a monogenic disease, correction of the gene defect in only one tissue may be sufficient to improve or to normalize the subject's condition. Examples of monogenic disease include Gaucher's disease (glucocerebrosidase deficiency), mucopolysaccharidosis (β -glucuronidase deficiency), hyperammonemia (ornithine transcarbamylase deficiency),
15 familial hypercholesterolemia (LDL receptor deficiency), hemophilia A (blood clotting factor VIII deficiency), phenylketonuria (phenylalanine hydroxylase deficiency), emphysema (α_1 -antitrypsin deficiency), Duchenne muscular dystrophy (dystrophin deficiency), and sickle-cell disease (β -globin deficiency).

There are various approaches to treating cancer via gene therapy. For
20 example, suicide genes that confer drug sensitivity can be transferred to cancer cells. Such transduced cancer cells are selectively eliminated due to their hypersensitivity to the drug. Gene therapy can also be used to transfer therapeutic genes that down-regulate oncogenes. Alternatively, cancer-promoting genes can be attacked using anti-sense genes, or targeted ribozymes. In another approach, recombinant antibody genes
25 can be introduced into a subject to produce antibodies that interfere with tumor cell functions. Genes can also be introduced into a subject that enhance the subject's anti-tumor immune response. Such genetic approaches to cancer therapy are described, for example, by Davis *et al.*, *Curr. Opin. Oncol.* 8:499 (1996), Rosenfeld and Curiel, *Curr. Opin. Oncol.* 8:72 (1996), Schmidt-Wolf and Schmidt-Wolf, *Ann. Hematol.* 73:207
30 (1996), Zhang and Russell, *Cancer Metasis. Rev.* 15:385 (1996), Blaese, *Scientific*

American, page 91 (June 1997), and Roth and Cristiano, *J. Natl. Cancer Inst.* 89:21 (1997).

In addition to monogenic diseases and cancer, gene therapy can be directed to infectious diseases, such as AIDS, arterial diseases, rheumatoid arthritis, and
5 degenerative neurological disorders.

There are numerous approaches to introduce a stress-regulated therapeutic gene to a subject, including the use of recombinant host cells that express a therapeutic gene in an *ex vivo* approach, delivery of naked nucleic acid encoding a therapeutic gene, use of a cationic lipid carrier with a therapeutic gene, and the use of
10 viruses that express the therapeutic gene, such as recombinant retroviruses, recombinant adeno-associated viruses, recombinant adenoviruses, and recombinant Herpes simplex viruses. See, for example, Rosenberg *et al.*, *Science* 242:1575 (1988), Wolff *et al.*, *Science* 247:1465 (1990), Breakfield and Deluca, *The New Biologist* 3:203 (1991), LaSalle *et al.*, *Science* 259:988 (1993), and Mulligan, *Science* 260:926 (1993).

15 Suitable recombinant viral vectors, include for example, adenoviral vectors (*e.g.*, Kass-Eisler *et al.*, *Proc. Nat'l Acad. Sci. USA* 90:11498 (1993); Kolls *et al.*, *Proc. Nat'l Acad. Sci. USA* 91:215 (1994); Li *et al.*, *Hum. Gene Ther.* 4:403 (1993); Vincent *et al.*, *Nat. Genet.* 5:130 (1993); and Zabner *et al.*, *Cell* 75:207 (1993); WO 94/26914, WO 93/9191), adenovirus-associated viral vectors (Flotte *et al.*, *Proc. Nat'l*
20 *Acad. Sci. USA* 90:10613 (1993); Ferrari *et al.*, *Nature Medicine* 11:1295 (1997)), alphaviruses such as Semliki Forest Virus and Sindbis Virus (Hertz and Huang, *J. Vir.* 66:857 (1992); Raju and Huang, *J. Vir.* 65:2501 (1991); Xiong *et al.*, *Science* 243:1188 (1989); U.S. Patent No. 5,091,309; WO 92/10578; WO 95/07994); herpes viral vectors (*e.g.*, U.S. Patent Nos. 4,769,331, 4,859,587, 5,288,641 and 5,328,688; and
25 international publication Nos. WO 94/14971 and WO 95/04139), parvovirus vectors (Koering *et al.*, *Hum. Gene Therap.* 5:457 (1994), pox virus vectors (Ozaki *et al.*, *Biochem. Biophys. Res. Comm.* 193:653 (1993); Panicali and Paoletti, *Proc. Nat'l Acad. Sci. USA* 79:4927 (1982)), pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:317 (1989); Flexner *et al.*, *Ann. N.Y.*
30 *Acad. Sci.* 569:86 (1989); U.S. Patent Nos. 4,603,112, 4,769,330 and 5,017,487; WO

89/01973), and retroviruses (e.g., Baba *et al.*, *J. Neurosurg* 79:729 (1993); Ram *et al.*, *Cancer Res.* 53:83 (1993); Takamiya *et al.*, *J. Neurosci. Res* 33:493 (1992); Vile and Hart, *Cancer Res.* 53:962 (1993); Vile and Hart, *Cancer Res.* 53:3860 (1993); U.S. Patent No. 5,219,740; EP 415,731; WO 90/07936; WO 91/0285, WO 94/03622; WO
5 93/25698; WO 93/25234; WO 93/11230; WO 93/10218). Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

Adenoviruses can be made replication-deficient, can infect quiescent or terminally differentiated cells, and can be purified to high titers. See, for example,
10 Kozarsky and Wilson, *Curr. Opin. Genet. Dev.* 3:499 (1993). In addition, adenovirus DNA does not integrate into the host genome, thus decreasing the risk of adenovirus-associated disease.

Herpes simplex virus-based vectors have the ability to deliver therapeutic genes to non-dividing cells, and the ability to infect many cell types in humans. See, for
15 example, Fields (ed.), *Virology*, pages 527-561 (Raven Press 1985), and Pepose and Lieb, *Invest. Ophthalmol. Vis. Sci.* 35:2662 (1994). Those of skill in the art are capable of constructing recombinant HSV viruses, using standard techniques. HSV-1 DNA can be obtained, for example, from commercial sources such as the American Type Culture Collection (ATCC No. VR-260). Martuza *et al.*, U.S. Patent No. 5,585,096 (1996), for
20 example, have described the production of replication-competent HSV to express a therapeutic gene in a subject. Due to a double mutation, these HSV vectors produce neither ribonucleotide reductase nor the product of the K34.5 gene.

High titer stocks of recombinant viruses capable of expressing therapeutic and transcription factor genes of a regulatory circuit can be obtained from
25 infected mammalian cells using standard methods. For example, recombinant HSV can be prepared in Vero cells, as described by Brandt *et al.*, *J. Gen. Virol.* 72:2043 (1991), Herold *et al.*, *J. Gen. Virol.* 75:1211 (1994), Visalli and Brandt, *Virology* 185:419 (1991), Grau *et al.*, *Invest. Ophthalmol. Vis. Sci.* 30:2474 (1989), Brandt *et al.*, *J. Virol. Meth.* 36:209 (1992), and by Brown and MacLean (eds.), *HSV Virus Protocols*
30 (Humana Press 1997).

Depending upon the particular use of gene therapy, it may be desirable to suppress the expression of an abnormal protein. This can be achieved by blocking the transcription or translation of the mutated gene product. For example, anti-sense molecules have been used to block the expression of gene products.

5 Alternatively, a stress-inducible expression vector can be constructed in which a regulatory element is operably linked to a nucleotide sequence that encodes a ribozyme. Ribozymes can be designed to express endonuclease activity that is directed to a certain target sequence in a mRNA molecule. See, for example, Draper and Macejak, U.S. Patent No. 5,496,698; McSwiggen, U.S. Patent No. 5,525,468; Chowrira
10 and McSwiggen, U.S. Patent No. 5,631,359; Robertson and Goldberg, U.S. Patent No. 5,225,337.

 In another approach, expression vectors can be constructed in which a regulatory element directs the production of RNA transcripts capable of promoting RNase P-mediated cleavage of mRNA molecules that encode the target protein. According to
15 this approach, an external guide sequence can be constructed for directing the endogenous ribozyme, RNase P, to a particular species of intracellular mRNA, which is subsequently cleaved by the cellular ribozyme. See, for example, Altman *et al.*, U.S. Patent No. 5,168,053; Yuan *et al.*, *Science* 263:1269 (1994); Pace *et al.*, international publication No. WO 96/18733; George *et al.*, international publication No. WO 96/21731; Werner
20 *et al.*, international publication No. WO 97/33991. Preferably, the external guide sequence comprises a ten to fifteen nucleotide sequence complementary to mRNA encoding a target protein of interest, and a 3'-NCCA nucleotide sequence, wherein N is preferably a purine. The external guide sequence transcripts bind to the targeted mRNA species by the formation of base pairs between the mRNA and the complementary
25 external guide sequences, thus promoting cleavage of mRNA by RNase P at the nucleotide located at the 5'-side of the base-paired region.

 In general, the dosage of a composition comprising a therapeutic vector having a regulatory circuit, such as a recombinant virus, will vary depending upon such factors as the subject's age, weight, height, sex, general medical condition and previous

medical history. The dosage will also depend upon the particular gene of interest and the disease or condition that is targeted for treatment.

Suitable routes of administration of therapeutic vectors include intravenous injection, intraarterial injection, intraperitoneal injection, intramuscular
5 injection, intratumoral injection, subcutaneous injection, and injection into a cavity that contains a tumor. Administration can be performed by continuous infusion or by single or multiple boluses.

A composition comprising therapeutic vectors of the present invention can be formulated according to known methods to prepare pharmaceutically useful
10 compositions, whereby vectors or viruses are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient subject. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example,
15 *Remington's Pharmaceutical Sciences, 19th Ed.* (Mack Publishing Co. 1995), and *Gilman's The Pharmacological Basis of Therapeutics, 7th Ed.* (MacMillan Publishing Co. 1985).

For purposes of therapy, a therapeutic vector, or a recombinant virus comprising such a vector, and a pharmaceutically acceptable carrier are administered to
20 a subject in a therapeutically effective amount. A combination of a therapeutic vector (or virus) and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient subject.

25 After administration, vectors comprising regulatory circuits described herein must be activated in the subject. A preferred method of activating such a circuit is to apply heat to the location that would benefit from expression of the therapeutic gene. Selective localized heating of the inducible genes in target tissue with the body can be achieved using either non-invasive or invasive procedures. Non-invasive heating
30 can be accomplished with focused ultrasound which has been shown to locally heat

tissues in situations where the acoustic path from the surface of the body to the target tissue has no interceding air and bone. See, for example, Lele, *J. Physiol.* 160:494 (1962). Transducers for delivering the ultrasound are designed with specific dimensions and shapes for high intensity ultrasound focusing for different anatomical regions of the body. These ultrasound transducers can be constructed in an array so that acoustic power can be phased and the heat targeting can be highly controlled and localized.

Heat can also be delivered non-invasively to localized areas of the body using an adaptive phased radiowave array. Microwave power at, for example, 915 MHz, can be delivered with adaptive feedback focusing to control the energy delivered and, thus, the temperature in a localized area. Fenn, U.S. Patent No. 5,251,645 (1993).

Localized heating within the body can also be performed by invasive procedures such as by introducing catheters and using imaging methods, such as 3D ultrasound or computerized tomography, to guide localization of a heating applicator in the target tissue. These applications can take the form of metal needles where heat is produced by connecting the ends of the needles that are outside the body to a source of radio-frequency power. Alternatively, the catheters could serve as guides for optical fibers to deliver laser energy to produce localized heating.

Local stress may also be applied by application of a chemical activator of stress promoters such as, for example, a heavy metal or a benzoquinone ansamycin compound. Local application may be achieved by direct injection into the target tissue. For many chemicals, the concentration needed to activate a stress promoter in cells of a particular organism is well known. Persons skilled in the art will know how to achieve the required concentration in a particular tissue or how to obtain the relevant information.

Unlike in the protein production setting where activation at a low stress threshold may be acceptable or even desired, in the gene therapy setting it is important that a regulatory circuit is only triggered at highest possible level of stress. Stress promoters are only strongly active at temperatures of 41-42°C and above in human cells. Such temperatures, corresponding to extreme fever, are only reached rarely in

humans. In fact, a prudent physician will do everything possible to prevent a patient from developing such fever to avoid consequences such as seizures. Thus, except under the most unusual circumstances, stress promoters will not be activated inadvertently in humans. Regulatory circuits can be built to have a similarly high threshold level of activation by carefully choosing a strictly stress-regulated promoter and, if necessary, introducing other modifications as discussed before to reduce the level of accumulation of mutated HSF.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

15

EXAMPLE 1

CONSTRUCTION AND OPERATION OF A TEST CIRCUIT

The exemplary test circuit contains two elements. The first element consists of a plasmid containing a stress promoter-regulated firefly luciferase gene. To prepare this construct, 10 µg of plasmid 173OR, described by Voellmy *et al.*, *Proc. Natl. Acad. Sci. USA* 89:4949 (1985), are digested with 25 units of restriction enzymes *Xho*I and *Hind*III for two hours at 37°C, using a digestion buffer suggested by the supplier (New England Biolabs, Inc., Beverly, MA). The digest is electrophoresed on a 0.9% agarose gel, and DNA fragments are visualized by ethidium bromide staining. A 2.7 kbp fragment is excised, electroeluted, purified by phenol-chloroform-isoamyl alcohol and chloroform extraction and ethanol precipitation, and resuspended in a small volume of water. The 2.7 kbp fragment contains the promoter and a portion of the RNA leader sequence of the human *hsp70B* gene. A 5 µg aliquot of pGL3-Basic Vector (Promega, Madison, WI), containing a promoter-less firefly luciferase gene, is similarly double-digested with *Xho*I and *Hind*III, purified by phenol-chloroform-isoamyl alcohol

and chloroform extraction and ethanol precipitation, and resuspended in a small volume of water. Standard ligation reaction is carried out containing about 1 µg of p1730R fragment and 0.25 µg of digested pGL3-Basic Vector. The ligation reaction is used to transform MC1061 *E. coli* host cells. Ampicillin-resistant transformants are recovered, and plasmid DNA is prepared from transformant cultures by a standard procedure. The identity of the intended construct, *hsp70B*-luciferase, in which the *hsp70B* promoter segment is inserted in the correct orientation immediately upstream from the luciferase-coding sequence is determined by extensive restriction analysis.

To functionally test the construct, HeLa cells are transfected by the Lipofectamine™ method (Gibco-BRL) with 2-10 µg of *hsp70B*-luciferase DNA per 60 mm dish containing 70%-confluent HeLa cells. One day after transfection, one of two parallel cultures is heat-treated at 42-44°C for 1 hour in a waterbath, and the parallel cultures are incubated for several hours at 37°C. Cells are harvested, extracts prepared and luciferase activity measured by a standard procedure. Readily measurable luciferase activity can be seen in extracts from heat-treated, transfected cultures, but not from transfected cultures that have not been heat-treated, or from untransfected cultures.

The second element consists of a plasmid containing an *HSF1* mutant gene, HSF1d202-316, which is described in Zuo *et al.*, *Mol. Cell. Biol.* 15:4319 (1995), and a functionally linked *hsp70B* promoter. To construct this plasmid, p1730R DNA is digested with *Bam*HI and *Eco*RI as described above, and a 2 kbp *Bam*HI-*Eco*RI fragment containing 3' nontranslated sequences from a *Drosophila hsp70* gene is isolated. Another aliquot of p1730R DNA is digested with *Eco*RI and *Hind*III, and a fragment about 5 kbp in length and containing plasmid sequences including an ampicillin resistance gene and *hsp70B* promoter and RNA leader sequences is isolated. Finally, a *Hind*III-*Bgl*II fragment about 1.8 kbp in length containing the *HSF1*d202-316-coding region is isolated from a pGem3Zf(+) plasmid clone carrying the mutated *HSF1* sequence (Zuo, J. (1994) Ph.D. Thesis, University of Miami, Miami, FL). The three fragments are co-ligated and transformed, and transformants analyzed as described before. The correct plasmid identified in this way, named *hsp70B*-mutated *HSF1*, contains, in a plasmid sequence background derived from p1730R, *hsp70B*

promoter and DNA leader sequences linked to the beginning of the mutated *HSF1* gene and *Drosophila* 3' nontranslated sequences linked to the end of the mutated *HSF1* gene.

To evaluate the test circuit consisting of a combination of the above two plasmids, parallel sets HeLa cell cultures are transfected with a plasmid expressing
5 luciferase constitutively (for example, pRL-CMV Vector (Promega)) as a positive control, with *hsp70B*-luciferase or co-transfected with both *hsp70B*-luciferase and *hsp70B*-mutated *HSF1*. To optimize the system, co-transfections should be carried out at different ratios of the two plasmids. One day after transfection, one set of cultures is subjected to 42-44°C/1 hour heat treatment, and all cultures are further incubated for
10 two to three days at 37°C. Cells are then harvested, extracts prepared, and luciferase activity measured by a standard procedure.

To verify equal transfection of cultures, all transfection solutions may contain a gene encoding enhanced green fluorescent protein, and transfection efficiency is monitored by counting fluorescing cells under a fluorescence microscope.
15 Alternatively, a portion of cells may be set aside at the time of harvest for cytometric determination of transfection efficiency. If the circuit is operating satisfactorily, co-transfected cells that have not been heat-treated should contain low luciferase activity, comparable to that of non-heat-treated cells transfected singly with *hsp70B*-luciferase. In contrast, heat-treated, co-transfected cells should show luciferase activity
20 that is orders of magnitude greater than that measured in unheated, co-transfected cells and at least one order of magnitude greater than that present in heat-treated cells singly transfected with *hsp70B*-luciferase. Luciferase activity in heat-treated, co-transfected cells will be equal or greater than that in cells transfected with the construct constitutively expressing luciferase.

EXAMPLE 2

CONSTRUCTION OF A CIRCUIT FOR THE
MASS PRODUCTION OF HUMAN GROWTH HORMONE

5 An example circuit for the production of human growth hormone contains the following two elements: *hsp70B*-mutated *HSF1* and a plasmid containing a cDNA gene encoding human growth hormone functionally linked to the *hsp70B* promoter. The latter plasmid can be plasmid 17hGHdhfr. Dreano *et al.*, *Gene* 49:1 (1986).

10 The operation of the circuit is as follows. HeLa cells transfected with p17hGHdhfr do not produce growth hormone in the absence of stress. When cells are stressed by a 42°C/1 hour heat treatment, expression of growth hormone is induced and can be measured in the medium by a standard radioimmunoassay, as described, for example, by Dreano *et al.*, *Gene* 49:1 (1986). Expression of growth hormone ceases
15 about one day after heat treatment. In contrast, expression of growth hormone continues in cells co-transfected with p17hGHdhfr and *phsp70B*-mutated *HSF1* for several days after heat treatment.

20

 Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of
25 ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention, which is defined by the following claims.

CLAIMS

1. A molecular circuit, comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress and by the transcription factor, wherein the first promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the second promoter and the gene of interest are operably linked.
2. The molecular circuit of claim 1, wherein a single nucleic acid molecule comprises the first nucleic acid molecule and the second nucleic acid molecule.
3. The molecular circuit of claim 1, wherein the transcription factor is a mutated heat shock transcription factor (HSF).
4. The molecular circuit of claim 3, wherein the mutated HSF is derived from a vertebrate HSF or from an insect HSF.
5. The molecular circuit of claim 4, wherein the vertebrate HSF is a mammalian HSF or an avian HSF.
6. The molecular circuit of claim 1, wherein the transcription factor is a chimeric transcription factor.
7. An expression vector comprising the molecular circuit of claim 2.
8. A set of expression vectors, comprising a first expression vector comprising the first nucleic acid molecule of claim 1, and a second expression vector comprising the second nucleic acid molecule of claim 1.

9. A molecular circuit comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress, wherein the first promoter and the transcription factor gene are operably linked, (b) a second nucleic acid comprising a gene encoding the transcription factor and a second promoter activatable by the transcription factor, wherein the second promoter and the transcription factor gene are operably linked, and (c) a third nucleic acid molecule that comprises a gene of interest and a third promoter activatable by the transcription factor, wherein the third promoter and the gene of interest are operably linked.

10. The molecular circuit of claim 9, wherein a single nucleic acid molecule comprises the first nucleic acid molecule and the second nucleic acid molecule.

11. The molecular circuit of claim 9, wherein a single nucleic acid molecule comprises the first nucleic acid molecule, the second nucleic acid molecule, and the third nucleic acid molecule.

12. An expression vector comprising the single nucleic acid molecule of claim 11.

13. A set of expression vectors, comprising a first expression vector comprising the first nucleic acid molecule of claim 9, a second expression vector comprising the second nucleic acid molecule of claim 9, and a third expression vector comprising the third nucleic acid molecule of claim 9.

14. A set of expression vectors, comprising a first expression vector that comprises the first and second nucleic acid molecules of claim 9, and a second expression vector that comprises the third nucleic acid molecule of claim 9.

15. A molecular circuit comprising (a) a first nucleic acid molecule that comprises a gene encoding a first transcription factor and a first promoter activatable by

stress, wherein the first promoter and the first transcription factor gene are operably linked, (b) a second nucleic acid comprising a gene encoding a second transcription factor and a second promoter activatable by the first transcription factor and the second transcription factor, wherein the second promoter and the second transcription factor gene are operably linked, and (c) a third nucleic acid molecule that comprises a gene of interest and a third promoter activatable by the second transcription factor, wherein the third promoter and the gene of interest are operably linked.

16. The molecular circuit of claim 15, wherein a single nucleic acid molecule comprises the first nucleic acid molecule and the second nucleic acid molecule.

17. The molecular circuit of claim 15, wherein a single nucleic acid molecule comprises the first nucleic acid molecule, the second nucleic acid molecule, and the third nucleic acid molecule.

18. An expression vector comprising the first, second, and third nucleic acid molecules of claim 15.

19. A set of expression vectors, comprising a first expression vector comprising the first nucleic acid molecule of claim 15, a second expression vector comprising the second nucleic acid molecule of claim 15, and a third expression vector comprising the third nucleic acid molecule of claim 15.

20. A set of expression vectors, comprising a first expression vector that comprises the first and second nucleic acid molecules of claim 15, and a second expression vector that comprises the third nucleic acid molecule of claim 15.

21. The molecular circuit of claim 1, wherein the gene of interest encodes a transactivator, and wherein the molecular circuit further comprises a nucleic acid molecule

comprising a second gene of interest and a promoter activatable by the transactivator, wherein the second gene of interest and the transactivator-activatable promoter are operably linked.

22. A molecular circuit, comprising (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a first promoter activatable by stress, wherein the first promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest, the transcription factor gene, and a second promoter activatable by the transcription factor, wherein the second promoter is operably linked with the gene of interest and the transcription factor gene.

23. The molecular circuit of claim 22, wherein a single nucleic acid molecule comprises the first nucleic acid molecule and the second nucleic acid molecule.

24. An expression vector comprising the single nucleic acid molecule of claim 23.

25. A set of expression vectors, comprising a first expression vector comprising the first nucleic acid molecule of claim 22, and a second expression vector comprising the second nucleic acid molecule of claim 22.

26. A recombinant eukaryotic host cell, comprising either the expression vector of any one of claims 7, 12, 18, or 24, or an expression vector set of any one of claims 8, 13, 14, 19, 20, or 25, wherein the host cell is selected from the group consisting of insect cell, avian cell, yeast cell, and mammalian cell.

27. A method of producing a protein of interest, comprising the steps of:

- (a) culturing the recombinant host cells of claim 26,
- (b) stimulating the first promoter by exposing the cultured recombinant cells to stress, and

(c) isolating the protein of interest from the cultured recombinant host cells, wherein the protein of interest is expressed by the gene of interest.

28. The method of claim 27, wherein the step (b) is achieved by heating the recombinant host cells.

29. The method of claim 27, wherein the recombinant host cell is a mammalian cell.

30. A virus, comprising the expression vector of any one of claims 7, 12, 18, or 24.

31. The virus of claim 30, wherein the virus is selected from the group consisting of adeno-associated virus, adenovirus, *Herpes simplex* virus, alphavirus, and pox virus.

32. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and either the expression vector of any one of claims 7, 12, 18, or 24, or an expression vector set of any one of claims 8, 13, 14, 19, 20, or 25.

33. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the virus of claim 30.

34. A method of treating a subject with a protein of interest, comprising the steps of:

(a) administering the pharmaceutical composition of either claim 32 or claim 33 to the subject, and


(b) applying heat to the area of the subject in need of the protein of interest, wherein the heat treatment results in the stimulation of the expression of the gene of interest.

35. A method of stimulating the expression of a gene of interest in a recombinant cell, comprising the steps of:


(a) producing a recombinant host cell by introducing into a host cell either the expression vector of any one of claims 7, 12, 18, or 24, or an expression vector set of any one of claims 8, 13, 14, 19, 20, or 25, and

(b) exposing the recombinant host cell to a condition of stress, wherein the stress exposure stimulates the first promoter to increase expression of the gene operably linked to the first promoter, which in turn, results in the stimulation of expression of the gene of interest.


1/5

*Fig. 1*


2/5

*Fig. 2*

3/5

*Fig. 3*

4/5

*Fig. 4*

5/5

-160 CGGGCCCGTTGCAAGATGGCGGCGCCATGCTGGGCCCGGGGCTGTGTGTGCGCAGCGGGCGGCGCGGCCCGGAAGGCTGGCGC
1 M D L P V G
-72 GGCGACGGCGTTAGCCCGGCCCTCGGCCCTCTTTGCGGCGCTCCCTCGGCCTATTCCCTCCTTGCTCGAGATGGATCTGCCCGTGGG
7 P G A A G P S N V P A F L T K I W T L V S D P D T D A L I C
19 CCCGGCGCGGGGGGCCAGCAACGTCCTGGCCCTTCTGACCAAGCTGTGGACCCTCGTGAGCGACCCGGACACCGACGCGCTCATCTGC
37 W S P S G N S F H V F D O G O F A K E V L P K Y F K H N N M
109 TGGAGCCCGAGCGGGAACAGCTTCCACGTGTCGACCAAGGCGCAGTTTGCCAAGGAGGTGCTGCCAAGTACTTCAAGCACAACAACATG
67 A S F V R O L N M Y G F R K V I V H I E O G G L V K P E R D D
199 GCCAGCTTCGTGCGGCGAGCTCAACATGTATGGCTCCGGAAGGTGGTCCACATCGAGCAGGGCGGCCGTGGTCAAGCCAGAGAGAGACGAC
97 T E F O H P C F L R G O E O L L E N I K R K V T S V S T L K
289 ACGGAGTTCAGCACCCATGCTTCTGCGTGCCAGGAGCAGCTCCTTGAGAACATCAAGAGAAAGTGACCAAGTGTGTCCACCTGAAG
127 S E D I K I R O D S V T K L L T D V O I M K G K O E C M D S
379 AGTGAAGACATAAAGATCCGCCAGGACAGCGTCAACAGCTGCTGACGAGCTGCAGCTGATGAAGGGGAAGCAGGAGTGCATGGACTCC
157 K L L A M K H E N E A L W R E V A S L R O K H A O O O K V V
469 AAGTCTTGGCCATGAAGCATGAGAATGAGGCTCTGTGGCGGGAGGTGGCCAGCCTTCGGCAGAAGCATGCCAGCAACAGAAAGTCGTC
187 N K L I O F L I S L V I O S N R I L G V K R K I P L M I N D S
559 AACAGCTCATTCACTTCTGATCTCACTGGTGCAGTCAAACCGGATCCTGGGGGTGAAGAGAAAGATCCCTTGATGCTGAACGACAGT
217 G S A H S M P K Y S R Q F S L E H V H G S G P Y S A P S P A
649 GGCTCAGCACATTCCATGCCAAGTATAGCGGCAGTTCCTCTGGAGCAGCTCCACGGCTCGGGCCCTACTCGGCCCTCCCGAGCC
247 Y S S S S L Y A P D A V A S S G P I I S D I T E L A P A S P
739 TACAGCAGCTCCAGCCTCTACGCCCTGATGCTGTGGCCAGCTCTGGACCATCATCTCCGACATCACCAGCTGGCTCCTGCCAGCCCC
277 M A S P G G S I D E R P L S S S P L V R V K E E P P S P P Q
829 ATGGCCTCCCCGGGGGAGCATAGACGAGAGGCCCTATCCAGCAGCCCCCTGGTGGGTGTCAAGGAGGAGCCCCCAGCCCGCTCAG
307 S P R V E E A S P G R P S S V D T L L S P T A L I D S I L R
919 AGCCCCGGGTAGAGGAGGCGAGTCCCGGGCGCCATCTTCGTGGACACCTTGTGCCCCGACCGCCCTATTGACTCCATCCTGGG
337 E S E P A P A S V T A L T D A R G H T D T E G R P P S P P P
1009 GAGAGTGAACCTGCCCGCCTCGTACAGCCCTACGGAGCGCAGGGGCCACAGGACCCGAGGGCCGCGCTCCCTCCCCCGGCC
367 T S T P E K C L S V A C L D K N E L S D H L D A M D S N L D
1099 ACCTCCACCCCTGAAAAGTGCTCAGCGTAGCCTGCCTGGACAAGAATGAGTCACTGAGTCACTGGATGCTATGACTCCAACTGGAT
397 N L O T M L S S H G F S V D T S A L L D L F S P S V T V P D
1189 AACCTGCAGACCATGCTGAGCAGCCACGGCTTCAGCGTGGACACAGTGCCTGCTGGACCTGTCAGCCCCCTGGTGACCGTGCCCGAC
427 M S L P D L D S S L A S I Q E L L S P Q E P P R P P E A E N
1279 ATGAGCCTGCCTGACCTTGACAGCAGCTGGCCAGTATCCAAGAGTCTCTCTCCAGGAGCCCCCAGGCTCCCGAGGAGAGAGAC
457 S S P D S G K O L V H Y T A Q P L F L L D P G S V D T G S N
1369 AGCAGCCCGGATTAGGGAAGCAGCTGGTGCCTACAGCAGCGCAGCGCTGTTCTGCTGGACCCCGGCTCCGTGGACACCGGAGCAAC
487 D L P V L F E L G E G S Y F S E G D G F A E D P T I S L L T
1459 GACCTGCCGCTGCTGTTGAGTGGGAGAGGGCTCTACTTCTCCGAGGGGACGGCTTCGCCGAGGACCCACCATCTCCCTGCTGACA
517 G S E P P K A K D P T V S
1549 GGCTCGGAGCTCCCAAAGCCAAGGACCCCATGTCTCTAGAGGGCCCGAGGAGTGGGCCAGCGCCACCCACCCACCCAGTGCAG
1639 GGCTGGTCTTGGGGAGGACGGGAGCCTCGCGGTCTTGGGCACTGGTGGGTGGCGGCCATAGCCCGAGTAGGACAAACGGGCTCGGGTC
1729 TGGGACGACCTCTGGTCAGGAGGTACCTGGCTGCCAGTCTGCCTTCCCAACCCGTGCTGCTGGTGGTGGTGGGCTTCA
1819 GCCACCTGGAGTACCTGCAGGTGTTGATAGTCAAGATTGATTTTGGATTTTACACAAGTGTCCCGTCCCGCTCCACAGAGA
1909 TACACAGATATATACACAGTGGATGGACGGACAAGACAGGACAGAGATCTATAACAGACAGGCTCTAAAAAAAAAAAAAAAAAAAA

Fig. 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/09748

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/63 C12N15/67 C12N15/85 C12N15/12 C12N5/10
C12N7/00 C12P21/02 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 35992 A (VICAL INC) 2 October 1997 (1997-10-02)	1,2,7,8, 21,26, 27,29, 32,35
A	page 8, line 24 -page 9, line 10; figure 1 page 13, line 21 -page 17, line 3 page 19, line 20 -page 22, line 12; claims 1-16 --- -/--	3-6, 9-20, 22-25, 28,30, 31,33,34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 October 1999

Date of mailing of the international search report

20/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/09748

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 38117 A (SALK INST FOR BIOLOGICAL STUDI ;EVANS ROLAND M (US); NO DAVID (US)) 16 October 1997 (1997-10-16)	9-20,26, 27,29, 30,32,35
A	page 27, line 4 - line 16; claims 1-42; figure 2	1-8, 21-25, 28,31, 33,34
A	WO 98 06864 A (US HEALTH ;MOONEN CHRIT (US)) 19 February 1998 (1998-02-19) page 11, line 27 - line 32; claims 1-9; figure 2; examples 1,2	1-35
A	ZUO J ET AL: "MULTIPLE LAYERS OF REGULATION OF HUMAN HEAT SHOCK TRANSCRIPTION FACTOR 1" MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 8, 1 August 1995 (1995-08-01), pages 4319-4330, XP002067471 ISSN: 0270-7306 cited in the application figures 1-3,5,6	1-35
A	XIA ET AL.: "Transcriptional activation of heat shock factor HSF1 probed by phosphopeptide analysis of factor 32P-labeled in vivo" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 15, 10 April 1998 (1998-04-10), pages 8749-8755, XP002117381 table 1	1-35

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09748

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9735992 A	02-10-1997	US 5891718 A	06-04-1999
WO 9738117 A	16-10-1997	AU 2557297 A	29-10-1997
		CA 2251466 A	16-10-1997
		CN 1215432 A	28-04-1999
		EP 0910652 A	28-04-1999
WO 9806864 A	19-02-1998	AU 4241697 A	06-03-1998
		EP 0922110 A	16-06-1999